Journal of Clinical and Aesthetic Dermatology最新文献

{"title":"Red-Light Photodynamic Therapy with 10% Aminolevulinic Acid (ALA) Following Microneedling in the Treatment of Facial Actinic Keratosis: Cosmetic and Clinical Outcomes.","authors":"Gary Goldenberg, Ziv Schwartz, Faraz Yousefian","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>We evaluated the cosmetic outcome and clearance of actinic keratoses (AKs) using photodynamic therapy (PDT) with microneedling-assisted delivery of 10% aminolevulinic acid (ALA) gel (Ameluz®, Biofrontera, Woburn, MA) with 30-minute incubation followed by 10-minute illumination with a red light (BF-RhodoLED®, 635nm, 37 J/cm²).</p><p><strong>Methods: </strong>Five subjects were treated with red light PDT using microneedling-assisted delivery of 10% ALA gel. ALA gel was applied on the face and incubated for 30 minutes without occlusion, followed by illumination with a red light for 10 minutes (635nm, 37 J/cm²). Follow-up (FU) visits were made at Weeks 1, 2, 4, and 8. The primary endpoints were changes in subject- and investigator-graded Global Aesthetic Improvement Scale (GAIS) scores and assessment of quality in wrinkle, color evenness, texture, spot, and pore analyses with Canfield Visia-CR imaging system. Secondary endpoints were: 1) AK clearance as quantified by the count of AKs at eight-week FU versus baseline and 2) safety as measured by subject-reported pain (10-point VAS scale) during red-light illumination and adverse events.</p><p><strong>Results: </strong>Investigator- and subject-graded GAIS scores showed a sharp increase to \"much improved\" at two weeks and increased to \"very much improved\" at eight weeks. There was an average 24.93-percent improvement in texture and an average 10.30-percent improvement in skin tone (color) evenness. AK lesion clearance ranged from 70 to 100 percent, with the mean at 89.2±14.9 percent. Three subjects achieved 100-percent clearance. The mean pain score during red-light illumination was 3.2±1.6. All subjects completed the study.</p><p><strong>Limitations: </strong>The study included a small number of subjects (N=5).</p><p><strong>Conclusion: </strong>Our results indicate that red light PDT using microneedling-assisted delivery of 10% ALA gel and a short 30-minute incubation is a safe and tolerable procedure producing good cosmetic outcomes in several skin quality parameters, such as texture and skin tone evenness, as well as an AK lesion clearance rate of 89.2 percent at Week 8, relatively low pain scores, and a reduced PDT treatment time.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"18 4","pages":"51-56"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12007660/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144058039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reversing Oxinflammation Associated with Glycative Stress and Formation of Advanced Glycation End Products with a Dietary Supplement Containing Rosemary Extract.","authors":"Anna Guiotto, Alessandra Pecorelli, Zoe Diana Draelos, Audrey Gueniche, Margarita Yatskayer, Diane B Nelson","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>Skin aging is accelerated by glycative stress, which promotes the accumulation of advanced glycation end products (AGEs) and impairs the extracellular matrix. A randomized, double-blinded, placebo-controlled trial evaluated a dietary supplement containing rosemary extract (BioR), demonstrating tissular and visible improvements in skin quality. The data reported herein evaluated markers associated with glycative stress and AGEs from skin biopsies and tape strips obtained following dietary supplement use.</p><p><strong>Methods: </strong>Female participants (N=104), aged 40 to 65 years, with moderate-to-severe skin dullness and roughness/texture, and mild-to-moderate erythema, pore size, and uneven pigmentation were randomized to BioR (n=52) or placebo ([PLB] n=52). Capsules were taken with food over 12 weeks. Subjects (n=16, BioR; n=16, PLB) underwent 3mm punch biopsies (volar upper arm) and tape stripping (16 tape strips, each; volar forearm) at baseline and 12 weeks for analysis of 4-hydroxynonenal protein adducts (4HNE [oxidative stress marker]) and AGEs.</p><p><strong>Results: </strong>Immunohistochemistry and ELISA revealed that levels of 4HNE protein adducts were significantly decreased from baseline in the BioR versus PLB group (<i>p</i><0.005; biopsies) and significantly decreased from baseline in the BioR group alone (<i>p</i><0.05; tape strips) at 12 weeks. Significant reductions in AGEs occurred in the BioR versus PLB group (<i>p</i><0.005; biopsies) at 12 weeks. No significant changes from baseline occurred in 4HNE protein adduct levels or AGEs in the PLB group.</p><p><strong>Conclusion: </strong>After 12 weeks, a dietary supplement containing rosemary extract led to significant reductions in a marker associated with oxidative stress, a component of glycation, and AGEs versus placebo in skin in addition to visible improvements in skin quality.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"18 3","pages":"34-38"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11932104/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143712114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biostimulatory Fillers to Treat Post-liposuction Skin Irregularities.","authors":"Stefania Guida, Ilaria Proietti, Claudio Conforti, Carmen Cantisani, Nicola Zerbinati, Giovanni Pellacani, Hassan Galadari","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Treatment of post-liposuction skin irregularities (PLSI), a complication of liposuction, can be challenging.</p><p><strong>Objective: </strong>Considering the increasing request of treatment of PLSI, the aim of this study is to evaluate the efficacy and safety of CaHA diluted/hyperdiluted to PLSI.</p><p><strong>Methods: </strong>A retrospective study on a total of eight PLSI areas in six women treated with CaHA diluted/hyperdiluted was performed. Efficacy was estimated on pictures of affected areas collected before and four months after treatment, according to the recently validated PLSI scale and Student's t-test for paired samples was performed to analyze data. Eventual adverse events were used to evaluate safety.</p><p><strong>Results: </strong>Our results showed a statistically significant improvement of number and depth of depressions and a trend toward reduction of skin laxity.</p><p><strong>Conclusion: </strong>This study reported the efficacy and safety of CaHA diluted/hyperdiluted for PLSI treatment. Larger studies are encouraged to support the results of this pilot study.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"18 3","pages":"39-41"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11932099/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143712098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Roflumilast Cream 0.3% for a Patient With Genital Psoriasis Refractory to Other Topical and Systemic Treatments: A Case Report.","authors":"Melodie Young","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Genital involvement is a frequent complication of plaque psoriasis (PsO) and is associated with substantial emotional and physical burden. We report a case of a male patient with genital PsO who did not respond to multiple systemic and topical therapies but achieved complete clearance with roflumilast cream 0.3% (a potent phosphodiesterase 4 inhibitor). After 28 weeks of initial treatment with guselkumab, body surface area (BSA) affected had fallen from 42 to 8 percent; however, new genital lesions were noted. After eight months of additional topical treatment, BSA affected had fallen to 2 percent, but the patient had developed gluteal cleft lesions as well. Over the next three years, several topical and systemic treatments were tried, but his genital and gluteal cleft disease persisted and intense pruritus developed. Based on concerns about continued topical corticosteroid use, the lack of efficacy observed thus far, and the potential for rebound flare, once-daily roflumilast cream 0.3% was initiated. At Week 8, BSA affected had fallen to 1 percent, and was limited to residual scalp disease (which had not been treated with roflumilast); the genitals and gluteal cleft were clear, with slight erythema present only on the scrotum. At 16 weeks, genital and gluteal cleft disease remained well-controlled with no evidence of active disease. Overall, roflumilast cream 0.3% was well tolerated with no pruritus, folliculitis, irritation, or contact dermatitis observed.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"18 3-4 Suppl 1","pages":"S24-S27"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11980900/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144048919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of Strontium Cream in Alleviating Pruritus in Hidradenitis Suppurativa.","authors":"Rubi Walker, Brindley Brooks, Steven Daveluy","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition with limited treatment options and a significant impact on quality of life. This prospective, open-label, real-world study aimed to evaluate the efficacy of strontium cream in alleviating pruritus in HS.</p><p><strong>Methods: </strong>Fifty participants completed baseline and one-week post-intervention surveys. Pruritus was assessed using a numeric severity scale and a qualitative survey on overall itch reduction.</p><p><strong>Results: </strong>Statistical analysis revealed a significant reduction in itching symptoms post-intervention, with mean itch scores decreasing from 3.80±0.90 at baseline to 2.28±1.50 post-intervention (<i>p</i><0.001). Participant feedback also indicated overall satisfaction, with 84 percent of participants willing to recommend the cream to other HS patients.</p><p><strong>Limitations: </strong>The study relied on self-reported data, which introduces subjectivity, and the absence of a control group limits causal inference.</p><p><strong>Conclusion: </strong>Strontium cream demonstrates promise as a therapeutic option for managing pruritus in HS, warranting further research.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"18 3","pages":"12-14"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11932098/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143712100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From Psyche to Skin: A Call for Interdisciplinary Care in the Management of Psychodermatologic Conditions.","authors":"Mary D Sun, Brandon R Block, Simran Ohri, Timothy Rice","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Despite increasing academic discourse surrounding psychodermatology, few dermatologists or psychiatrists demonstrate a clear understanding of the field. Barriers to physician awareness are double-edged, stemming from both inadequate educational opportunities and patient non-disclosure of psychodermatologic symptoms during clinical encounters. It is crucial that medical practitioners, especially in the field of dermatology, become accustomed to recognizing, diagnosing, and treating psychocutaneous disorders, which disproportionately affect members of historically marginalized populations. In this commentary, we propose recommendations for pedagogic supplements to be implemented throughout medical, post-graduate, and post-residency education to build familiarity with this subdiscipline and confidence in managing its associated conditions. In particular, we endorse the integration of components of psychiatry education into dermatology residency training and current practice, as skin symptoms tend to be more openly disclosed than mental health struggles, so dermatologists are often the first physicians to encounter many of these conditions. We also advocate for interdisciplinary collaboration to bridge the gap between the uniformity of standard specialty training and the complexity of psychocutaneous disease.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"18 3","pages":"67-70"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11932102/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143712112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interpreting Safety Analyses in Psoriasis Clinical Trials.","authors":"Matthew Zirwas, Cynthia Trickett, Joe Gorelick, Kejia Wang, Keith Wittstock, Chaya Rosenberg, Douglas DiRuggiero","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Clinical trials are designed to evaluate the efficacy and safety of new drugs. However, greater focus is often placed on efficacy rather than safety. This review article discusses the fundamentals involved in evaluating the safety of a new drug. In addition, the principal challenges involved in the collection, analysis, reporting, and interpretation of safety data in clinical trials are described using relevant examples. These challenges include the fact that clinical trials are generally limited in size and duration, exclude high-risk populations, and have limited statistical power to detect rare but potentially serious adverse events (AEs) that might occur in real-world situations. Reporting of safety data across clinical trials is also inconsistent. A thorough understanding of the interpretation of safety data, especially the appropriate use of exposure-adjusted incidence rates (EAIRs) in relation to AEs, as well as the importance of comparing rates to those reported in the general population and in patients with psoriasis, is vital for making a well-informed assessment of the safety of a new drug. The information provided in this article could be useful to healthcare providers who must evaluate a large volume of safety data when providing evidence-based treatment suggestions and recommendations to their patients.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"18 3-4 Suppl 1","pages":"S16-S23"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11980901/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143991608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Impact of Acne Scarring on Quality of Life, Willingness-to-pay, and Time Trade-off: A Cross-sectional Analysis.","authors":"Henriette De La Garza, Nicole Trepanowski, Rene Flores, Poom Visutjindaporn, Nicole Patzelt, Neelam A Vashi","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>We sought to evaluate the impact of the presence of acne scarring in patients with acne vulgaris on quality of life as assessed by the Dermatology Life Quality Index (DLQI) and the Cardiff Acne Disability Index (CADI); disease severity using the Investigator's Global Assessment of Acne (IGA); and health utility measures including willingness-to-pay, time trade-off, time spent on concealment, and percent of income willing to exchange for resolution of disease.</p><p><strong>Methods: </strong>We conducted a cross-sectional, single-institution survey.</p><p><strong>Results: </strong>In total, 94 patients with acne vulgaris participated, of which 53.2 percent had acne scarring and 46.8 percent did not. The presence of acne scarring was associated with higher DLQI, CADI, and IGA scores. Utility measures including willingness-to-pay, time trade-off, concealment time, and percent of income willing to exchange for resolution of disease were similar for participants with and without scarring. For participants with and without scarring, a greater impairment of quality of life as assessed by the DLQI was positively correlated with WTP25, percent of monthly income, IGA, and the CADI.</p><p><strong>Limitations: </strong>As the study design was single-site and cross-sectional, and therefore results may not be generalizable.</p><p><strong>Conclusion: </strong>The presence of acne scarring significantly impacts quality of life. A greater impairment of quality of life in patients with acne vulgaris correlates positively with severity of acne and some measures of health economics. Interventions to minimize or prevent acne scarring may reduce psychosocial burden of disease.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"18 3","pages":"71-73"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11932101/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143712115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improving Knowledge and Awareness of Diabetes-associated Skin Manifestations in a Resource Limited Setting: A Video Education Pilot Study.","authors":"Angelica Rose Carnemolla, Eleanor Tung-Hahn, Gabriela Solorzano, Michael Farid, Nathan Quint, Cheryl Campbell, Rebecca Tung, Teresa Pettersen","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>Although skin findings in patients with diabetes mellitus (DM) are common, many patients are unaware of these associations. A pilot study using an educational video was conducted to assess the effectiveness of a video-based tool in evaluating and enhancing the knowledge of patients with Type 2 diabetes about the cutaneous manifestations of their disease.</p><p><strong>Methods: </strong>An instructional video in English and Spanish highlighting DM-associated skin conditions was created. This included xerosis, diabetic dermopathy, acanthosis nigricans (AN), acrochordons, infections, hidradenitis suppurativa (HS), wound healing, and cancer incidence. A convenience cohort of patients with diabetes were included. Participants completed a 10-question survey to assess their knowledge of DM-associated skin conditions either after watching the instructional video or without viewing it. A history-based questionnaire was also administered.</p><p><strong>Results: </strong>Fourty-five participants were enrolled. Thirty participants viewed the video, and 15 controls did not prior to completing the knowledge survey. The average total score (69%) in participants who watched the video was significantly better than controls (49%). Fourty-two percent of participants reported no prior knowledge of DM-associated cutaneous effects. Greater than half of this cohort endorsed a history of xerosis, acrochordons, and diabetic dermopathy. More than 40 percent of participants affirmed having AN and infection of the skin or nails. Twenty-nine percent had a history of foot ulcers, and 13 percent had cellulitis in the past.</p><p><strong>Limitations: </strong>This was a pilot study with a small sample size, limiting generalizability.</p><p><strong>Conclusion: </strong>These findings demonstrate the effectiveness of bilingual video education to enhance knowledge of DM-associated skin manifestations. Given the limited awareness of and high self-reported incidence of DM-associated cutaneous disorders, accessible educational resources like this video could help patients better recognize these entities and seek appropriate treatment.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"18 3-4 Suppl 1","pages":"S34-S37"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11980902/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144058442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Review of Glucagon-like Peptide-1 in Dermatology.","authors":"Willmar Patino, Amanda Thomas, Sanjana Jain, James Q Del Rosso, Naiem T Issa","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>Glucagon-like peptide-1 (GLP-1) is a hormone produced in response to meal intake by endocrine intestinal cells. GLP-1 binds to its receptors which are expressed on various cells throughout the body. GLP-1 receptors (GLP-1R) have become a target for the treatment of diabetes mellitus and weight loss, and GLP-1 receptor agonist (GLP-1RA) use has become more common among patients. In addition to the anti-hyperglycemic effects, recent studies have exhibited anti-inflammatory effects of GLP-1RAs. Current research surrounding GLP-1Rs and GLP-1R agonism in dermatology is limited. This review aims to describe the current knowledge of GLP-1Rs and GLP-1RA use in dermatology and suggest future directions.</p><p><strong>Methods: </strong>A literature search focused on GLP-1RAs and their effect on cutaneous disease processes was performed across various databases. The databases were searched through May 2024.</p><p><strong>Results: </strong>The use of GLP-1RAs have shown promising anti-inflammatory effects and improvement in wound healing, psoriasis, and hidradenitis suppurativa. Several cutaneous adverse reactions to GLP-1RAs were also identified with injection site pruritus, erythema, and rash being the most commonly reported.</p><p><strong>Limitations: </strong>Current literature is limited to case reports and small-scale studies.</p><p><strong>Conclusion: </strong>The literature suggests anti-inflammatory effects of GLP-1RAs may provide direct benefit in the treatment of dermatologic conditions independent of glucose control in addition to indirect improvement via modulation of blood glucose and weight loss. Further studies investigating the implications of GLP-1RA use and the possible therapeutic potential of GLP-1RAs in inflammatory skin conditions are warranted.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"18 3","pages":"42-50"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11932103/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143712075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}